

February 10, 2026

The Honorable Will Carpenter, Chairperson
House Committee on Health and Human Services
300 SW 10th Avenue, Room 112-N
Topeka, Kansas 66612

Dear Representative Carpenter:

SUBJECT: Fiscal Note for HB 2676 by House Committee on Health and Human Services

In accordance with KSA 75-3715a, the following fiscal note concerning HB 2676 is respectfully submitted to your committee.


HB 2676 would enact the Pharmacist Practice Authority Act. The Act would permit pharmacists to initiate therapy for a condition consisting of medications and durable medical equipment: (1) if the condition does not require a new diagnosis; (2) is minor and generally self-limiting; (3) has a test that is used to guide diagnosis or clinical decision-making that is waived under the federal clinical laboratory improvement amendments of 1988; or (4) in the professional judgement of a pharmacist, constitutes a patient emergency.

Aa pharmacist would be required to independently determine if a specific act that would be applicable to the bill is: (1) expressly prohibited by the Pharmacy Act or other law; (2) consistent with the pharmacist's education, training, and experience; and (3) within the accepted standard care that would be provided in a similar setting by a reasonable and prudent pharmacist with similar education, training, and experience. The bill would take effect upon its publication in the *Kansas Register*.

With the enactment of HB 2676, the Board of Pharmacy states that staff would need to spend time on initial implementation of the bill's provisions, including updating webpages and staff training; however, the Board indicates this could be done within existing resources. In future fiscal years, the Board states there could be an increase in complaints, investigations, and disciplinary actions because of the expansion of practice. The Board indicates investigations or disciplinary actions could be complex and require additional subject matter experts to document

and testify to the professional standard of care or attorneys to litigate cases; however, the Board states it would not request any increased expenditure authority or additional positions until there would be a demonstrated need. The Board did not estimate a fiscal effect. Any fiscal effect associated with HB 2676 is not reflected in *The FY 2027 Governor's Budget Report*.

Sincerely,

A handwritten signature in black ink, appearing to read "Adam C. Proffitt" with a stylized flourish at the end.

Adam C. Proffitt
Director of the Budget

cc: Alexandra Blasi, Board of Pharmacy